MMRF PRESS RELEASES
Music Legends Headline Multiple Myeloma Research Foundation's 14th Annual Fall Gala
Diana Krall and Paul Simon Join Premier Fundraising Event to Help Develop More Effective Cancer Treatments
Norwalk, CT — July 17, 2010
The Multiple Myeloma Research Foundation (MMRF) today announced that it will honor famed pianist and vocalist Diana Krall and her sister, Michelle Wigmore, with the Spirit of Hope Award at the 14th annual MMRF Fall Gala, scheduled to be held October 30, 2010, in Greenwich, Connecticut. Krall, a member of the MMRF’s Honorary Board of Directors, will also provide a performance as the event’s featured artist. Legendary singer and songwriter Paul Simon will also perform as the MMRF’s special guest.
“It is an honor for my sister, Michelle, and I to be recognized by the MMRF – an organization that has helped so many families like ours who have been touched by this terrible disease,” said Krall, whose mother died of multiple myeloma, an incurable blood cancer, in 2002. “It is our hope that, by continuing to raise awareness and research funds through events like this, we can play a role in helping the MMRF bring patients treatments that will extend their lives and give them more precious times with their families.”
Emmy Award-winning broadcast journalist and New York Times best-selling author Deborah Norville will join the evening’s celebrity line-up by serving as Mistress of Ceremonies. It is Norville’s ninth year in this special role.
“We are overjoyed that Diana Krall, Paul Simon and Deborah Norville have all come together in honor of the multiple myeloma patients and families courageously fighting this devastating disease and who stand by our side in supporting our urgent work to bring patients the treatments they need,” said Kathy Giusti, Founder and CEO of the MMRF and a myeloma patient.
Hervé Hoppenot, President of Novartis Oncology, will serve as the event’s Corporate Chair and will be honored with the Corporate Leadership Award in recognition of the Novartis’ commitment to developing innovative new treatments for multiple myeloma and other orphan cancers. In addition, Michael Reinert, Executive Vice President of Business & Legal Affairs for the Universal Motown Republic Group, a division of UMG Recordings, Inc., will be honored with the Courage and Commitment Award. Reinert, a multiple myeloma patient, recently wrote and starred in his first play “So Tell Me, What Can I Do”.
The MMRF Fall Gala is the largest and most prominent fundraising event in Connecticut’s Fairfield County. All funds raised will support the development of new treatments for multiple myeloma. To purchase tickets to the MMRF Fall Gala, donate an auction item or join a committee, please email firstname.lastname@example.org or call 888-584-5463.
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $140 million since its inception to fund nearly 120 laboratories worldwide, including 40 new compounds and approaches in clinical trials and pre-clinical studies and has facilitated 25 clinical trials through its sister organization, the Multiple Myeloma Research Consortium (MMRC). As exceptional stewards of its donor’s investments, the MMRF consistently surpasses its peers in fiscal responsibility. For more information about the MMRF, please visit www.themmrf.org.
About Multiple Myeloma
Multiple myeloma is an incurable blood cancer. The five-year relative survival rate for multiple myeloma is approximately 38 percent, one of the lowest of all cancers. In 2010, more than 20,000 adults in the United States will be diagnosed with multiple myeloma and nearly 11,000 people are predicted to die from the disease.